Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1524

Prof Kees Melief - Leiden University Medical Center, Leiden, Netherlands

Prof Kees Melief speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study looking at the HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer.

Prof Melief discusses the favourability of cancer vaccines due to the way they can be easily applied to large numbers of patients, their low cost and that when combined with chemotherapy and immunotherapy they can have great benefit.

He reports that the focus is on virus-induced cancers as the antigens are expressed in all cancer cells making them very good targets.


Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation